Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14760380 | 0.83 | HTR6 (0.50) | L3MBTL1HTTMAPTPKMMMP2 | |
| SCHEMBL3834757 | 0.81 | RAPGEF4 (0.65) | RAPGEF4CA1CA2L3MBTL1HTT | |
| SCHEMBL23699019 | 0.79 | RAPGEF4 (0.61) | RAPGEF4CA1CA2L3MBTL1HTT | |
| SCHEMBL5535689 | 0.79 | RAPGEF4 (0.61) | RAPGEF4CA1CA2L3MBTL1HTT | |
| SCHEMBL7641128 | 0.79 | RAPGEF4 (0.61) | RAPGEF4CA1CA2L3MBTL1HTT | |
| SCHEMBL3188642 | 0.79 | RAPGEF4 (0.61) | RAPGEF4CA1CA2L3MBTL1HTT | |
| SCHEMBL28592804 | 0.78 | RAPGEF4 (0.74) | RAPGEF4CA1CA2L3MBTL1HTT | |
| SCHEMBL21590225 | 0.78 | RAPGEF4 (0.52) | RAPGEF4CA1CA2L3MBTL1HTT | |
| SCHEMBL28449000 | 0.77 | RAPGEF4 (0.51) | RAPGEF4CA1CA2L3MBTL1HTT | |
| SCHEMBL2457308 | 0.76 | RAPGEF4 (0.58) | RAPGEF4CA1CA2L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100221647-A1 | PYRROLE CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2010-09-02 | — | — | US | claimed |
| EP-4619402-A1 | GPR17 MODULATORS AND USES THEREOF | Myrobalan Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2024-09-12 | — | — | US | disclosed |
| WO-2024114814-A1 | JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2024-06-06 | — | — | WO | disclosed |
| EP-4377318-A1 | PYRROLO [2, 3-B] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF | BeiGene, Ltd. (KY) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024104462-A1 | GPR17 MODULATORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2024-05-23 | — | — | WO | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794898-A | 3-pyrrolylsulfonamide compounds as GPR17 antagonists | 瑞文德医疗公众有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023168686-A1 | SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-14 | — | — | WO | disclosed |
| US-8067138-B2 | Pyrrole containing photoconductors | XEROX CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067138-B2 | Pyrrole containing photoconductors | XEROX CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067138-B2 | Pyrrole containing photoconductors | XEROX CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100221647-A1 | PYRROLE CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221647-A1 | PYRROLE CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221647-A1 | PYRROLE CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2010-09-02 | — | — | US | disclosed |
| EP-2094699-A2 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | Sanofi-Aventis (FR) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008046982-A2 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2008-04-24 | — | — | WO | disclosed |
| EP-1664043-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028475-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | GPR3, GPR27, GPR65 | RAPGEF4 2299/4885CA1 2947/4885CA2 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.